DA
REGN icon

Denali Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Denali Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Buy
500
+100
+25% +$76.6K 0.04% 258
2025
Q4 		$309K Buy
+400
New +$272K 0.03% 286
2021
Q3 		– Sell
-100
Closed -$56K – 314
2021
Q2 		$56K Hold
100
– – 0.02% 175
2021
Q1 		$47K Buy
+100
New +$48.7K 0.01% 227
2020
Q3 		– Sell
-100
Closed -$62K – 397
2020
Q2 		$62K Buy
+100
New +$56.8K 0.01% 317

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Denali Advisors's REGN Position: Q1 2026 in Review

Denali Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q1 2026, buying an estimated $76.6K and bringing the position to 500 shares worth $386K. The position accounts for 0.04% of the portfolio, ranked #258.

Denali Advisors first reported a position in REGN in Q2 2020 and has held it in 5 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Denali Advisors held 500 shares of Regeneron Pharmaceuticals worth $386K as of Q1 2026.
  • Denali Advisors bought 100 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $76.6K.
  • Regeneron Pharmaceuticals made up 0.04% of Denali Advisors's portfolio in Q1 2026, its #258 holding.
  • Denali Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 5 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Denali Advisors's 13F filing for Q1 2026, filed 8 May 2026.